Subscription demand is red-hot! Altimeter CEO reveals that the Anthropic (ANT.US) IPO was oversubscribed by 10-20 times.
Altimeter Capital CEO Brad Gerstner revealed at an event on Monday that the initial public offering (IPO) of Anthropic was in extremely high demand, with the offering oversubscribed by 10 to 20 times.
Altimeter Capital CEO Brad Gerstner revealed at an event on Monday that the initial public offering (IPO) of Anthropic (ANT.US) has seen extremely strong subscription demand, with the offering oversubscribed by 10 to 20 times. He also said his investment firm has submitted an indication of interest to subscribe for US$5 billion worth of new shares.
Speaking at the "Silicon Valley & The World" summit hosted by Semafor, Gerstner said this subscription amount is the largest new-share application in Altimeter Capital's 20-year history.
It is understood that Anthropic plans to list on Nasdaq on Thursday. This IPO is a milestone event for the AI industry and will also serve as a touchstone for the AI computing power sector and related companies. Earlier reports said Anthropic's IPO has already attracted orders about six times the number of shares available for subscription. The AI lab is expected to announce the final IPO offer price and share allocation results on Wednesday.
Gerstner said: "I think the industry is moving away from the past three and a half years, which were dominated by AI infrastructure, toward a cycle of intelligent models and application deployment. And in the intelligence sector, there are really only two core names to invest in: OpenAI and Anthropic. We have heavy positions in both companies."
Gerstner voices support for Jensen Huang
The investor also discussed the current turmoil at NVIDIA Corporation (NVDA.US), offering a relatively cautious view on Jensen Huang's departure. He said Huang "engaged in very inappropriate personal conduct," and that Huang had messaged him seeking support; Gerstner added that NVIDIA Corporation is vital to the country's future security and that the board cannot afford to make the wrong decision.
On the previous Friday, Gerstner and Atreides Management CEO Gavin Baker sent a letter to NVIDIA Corporation's board, calling for a prudent, unhurried and deliberate process in selecting a new leader, keeping all options open, including the option of Huang's return.
Gerstner is also one of the key drivers behind Trump-related investment entities and founded Altimeter in Boston in 2008. According to the latest disclosure filings, Altimeter's holdings include SpaceX (SPCX.US), Astera Labs (ALAB.US), Meta (META.US), Cerebras Systems (CBRS.US), Ciena (CIEN.US), NVIDIA Corporation and Micron Technology, Inc. (MU.US).
Key points of the Anthropic IPO
The AI company is targeting a valuation of US$1.4 trillion. That is down from the US$2 trillion target reported several months ago, but still significantly above the US$1.1 trillion expectation given by some Wall Street institutions during the worst period of the tech stock selloff.
Compiled data show that Anthropic and some of its investors plan to raise up to US$90.4 billion in total through this IPO plus a separate private placement. Combined, the two fundraisings would exceed SpaceX's US$75 billion base financing plan and become the largest listing fundraising in history.
Retail investor perspective: sentiment is hot but subscription willingness is low
On the social platform Stocktwits, overall retail sentiment toward Anthropic is extremely bullish, but some traders expect the stock price to come under pressure in the short term. An ongoing poll on Stocktwits shows that at least 67% of participating users do not plan to take part in this IPO.
One trader commented: "If ANT lists during a broad market downturn, the damage will be even greater."
"The market needs to stabilize first before it can absorb another AI giant of this size. Liquidity is already tight, and the Federal Reserve is sending risk warnings. Going long now is like swimming against the tide. It's better to wait on the sidelines until the situation becomes clearer than to keep losing money."
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






